|
EP2558128B1
(en)
|
2010-04-14 |
2016-12-21 |
Roger Williams Medical Center |
Methods and compositions for treating hiv
|
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
BR112013018311A2
(pt)
*
|
2011-01-18 |
2017-03-21 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
|
|
SG10201806573TA
(en)
|
2012-05-25 |
2018-09-27 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
|
WO2014055771A1
(en)
*
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
WO2014055657A1
(en)
*
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP3653212B1
(en)
|
2012-12-20 |
2023-04-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
PT3613439T
(pt)
*
|
2013-02-15 |
2021-05-12 |
Univ California |
Recetor de antigénio quimérico e métodos de utilização do mesmo
|
|
PL2958943T3
(pl)
|
2013-02-20 |
2020-04-30 |
The Trustees Of The University Of Pennsylvania |
Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
|
|
ES2814962T3
(es)
|
2013-02-20 |
2021-03-29 |
Novartis Ag |
Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
|
|
JP6493692B2
(ja)
|
2013-03-15 |
2019-04-10 |
セルジーン コーポレイション |
修飾されたｔリンパ球
|
|
ES3058841T3
(en)
|
2013-03-15 |
2026-03-13 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
PL2997141T3
(pl)
|
2013-05-13 |
2023-02-06 |
Cellectis |
Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
|
|
CN113801895A
(zh)
*
|
2013-09-23 |
2021-12-17 |
威尔逊沃夫制造公司 |
遗传修饰动物细胞的改进方法
|
|
CN103589742A
(zh)
*
|
2013-11-07 |
2014-02-19 |
申峰 |
嵌合体抗原受体胞内段的基因及其编码蛋白
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3808410A1
(en)
|
2013-12-20 |
2021-04-21 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
EP4420663A3
(en)
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
CN106414748B
(zh)
*
|
2014-02-14 |
2021-05-28 |
得克萨斯州大学系统董事会 |
嵌合抗原受体及制备方法
|
|
GB201405845D0
(en)
*
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
SI3888674T1
(sl)
*
|
2014-04-07 |
2024-08-30 |
Novartis Ag |
Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
|
|
CN112877291A
(zh)
*
|
2014-04-10 |
2021-06-01 |
西雅图儿童医院 (Dba西雅图儿童研究所) |
基因修饰的t细胞产品、其制备方法和用途
|
|
CN106459924A
(zh)
*
|
2014-04-23 |
2017-02-22 |
得克萨斯州大学系统董事会 |
用于疗法中的嵌合抗原受体(car)及其制备方法
|
|
PL3689899T3
(pl)
|
2014-04-25 |
2022-01-31 |
2Seventy Bio, Inc. |
Chimeryczne receptory antygenowe promotora mnd
|
|
CA2946552A1
(en)
|
2014-04-25 |
2015-10-29 |
Bluebird Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
|
DK3166968T3
(da)
|
2014-05-02 |
2021-12-06 |
Univ Pennsylvania |
Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
|
|
DK3151672T3
(da)
*
|
2014-06-06 |
2021-02-01 |
Bluebird Bio Inc |
Forbedrede t-celle-sammensætninger
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
BR112017001818A2
(pt)
*
|
2014-07-29 |
2017-11-21 |
Pfizer |
receptores antigênicos quiméricos específicos para egfrviii para imunoterapia de câncer
|
|
RU2020117196A
(ru)
|
2014-08-19 |
2020-10-15 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
WO2016073602A2
(en)
*
|
2014-11-05 |
2016-05-12 |
Juno Therapeutics, Inc. |
Methods for transduction and cell processing
|
|
SMT201900596T1
(it)
|
2014-12-12 |
2019-11-13 |
Bluebird Bio Inc |
Recettori chimerici di antigene per bcma
|
|
IL320860A
(en)
*
|
2014-12-19 |
2025-07-01 |
Dana Farber Cancer Inst Inc |
Chimeric antigen receptors and methods of using them
|
|
IL253149B2
(en)
|
2014-12-29 |
2023-11-01 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
US20180002435A1
(en)
|
2015-01-26 |
2018-01-04 |
Cellectis |
mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS
|
|
US11161907B2
(en)
*
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
IL287914B2
(en)
|
2015-02-24 |
2025-10-01 |
Univ California |
Linkage-activated transcription switches and methods of using them
|
|
CN115537396A
(zh)
|
2015-03-27 |
2022-12-30 |
哈佛学院校长同事会 |
经过修饰的t细胞及其制备和使用方法
|
|
IL303972A
(en)
|
2015-04-08 |
2023-08-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
JP6975643B2
(ja)
*
|
2015-05-13 |
2021-12-01 |
シーエスエル ベーリング ジーン セラピー インコーポレイテッド |
レンチウイルスベクターのバイオ生産法
|
|
MX2017014822A
(es)
|
2015-05-18 |
2018-04-30 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
|
|
EP4218778A3
(en)
|
2015-05-28 |
2023-08-23 |
Kite Pharma, Inc. |
Diagnostic methods for t cell therapy
|
|
MA43343A
(fr)
*
|
2015-05-28 |
2021-04-07 |
Kite Pharma Inc |
Méthodes de conditionnement de patients pour la thérapie cellulaire t
|
|
HK1255815A1
(zh)
*
|
2015-07-16 |
2019-08-30 |
Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center |
治疗腹膜癌的组合物和方法
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
HK1256087A1
(zh)
|
2015-08-07 |
2019-09-13 |
Seattle Children's Hospital, Dba Seattle Children's Research Institute |
用於实体瘤靶向的双特异性cart细胞
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
EP3364969A4
(en)
|
2015-10-20 |
2019-07-10 |
Kite Pharma, Inc. |
METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY
|
|
JP7092662B2
(ja)
|
2015-10-30 |
2022-06-28 |
チルドレンズ ナショナル メディカル センター |
ナイーブｔ細胞集団からのｈｐｖ抗原特異的ｔ細胞の生成
|
|
CN105331585A
(zh)
|
2015-11-13 |
2016-02-17 |
科济生物医药（上海）有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
|
US20210206826A1
(en)
*
|
2015-11-19 |
2021-07-08 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
PL3377618T3
(pl)
*
|
2015-11-19 |
2021-05-31 |
Novartis Ag |
Bufory do stabilizacji preparatów lentiwirusowych
|
|
CN116121281B
(zh)
|
2015-11-27 |
2026-01-02 |
卡瑟里克斯私人有限公司 |
经遗传修饰的细胞及其用途
|
|
IL259576B
(en)
|
2015-12-04 |
2022-09-01 |
Novartis Ag |
grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
GB201522097D0
(en)
|
2015-12-15 |
2016-01-27 |
Cellular Therapeutics Ltd |
Cells
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
BR112018013914A2
(pt)
|
2016-01-08 |
2018-12-11 |
Univ California |
polipeptídeos heterodiméricos condicionalmente ativos e métodos de utilização deste
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
WO2017173349A1
(en)
|
2016-04-01 |
2017-10-05 |
Kite Pharma, Inc. |
Bcma binding molecules and methods of use thereof
|
|
PT3436079T
(pt)
|
2016-04-01 |
2021-10-06 |
Kite Pharma Inc |
Recetores de antigénios quiméricos e de células t e métodos de uso
|
|
UA123276C2
(uk)
|
2016-04-01 |
2021-03-10 |
Кайт Фарма, Інк. |
Химерний рецептор та спосіб лікування пухлини або злоякісного новоутворення
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
ES2937699T3
(es)
|
2016-04-22 |
2023-03-30 |
Crage Medical Co Ltd |
Composiciones y métodos de inmunoterapia celular
|
|
CN118165113B
(zh)
*
|
2016-04-26 |
2025-10-28 |
恺兴生命科技(上海)有限公司 |
一种改善免疫应答细胞功能的方法
|
|
EP3455261B1
(en)
|
2016-05-13 |
2022-08-03 |
BioAtla, Inc. |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
JP7373991B2
(ja)
|
2016-07-15 |
2023-11-06 |
ビラクタ セラピューティクス，インク． |
免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP3515475B1
(en)
|
2016-09-21 |
2024-05-01 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
EP3529361B1
(en)
|
2016-10-20 |
2021-03-24 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
ES2916335T3
(es)
|
2016-10-20 |
2022-06-30 |
Celgene Corp |
Receptores de antígeno quimérico heterodimerizable basados en cereblon
|
|
BR112019009099A2
(pt)
|
2016-11-04 |
2019-07-16 |
Bluebird Bio Inc |
composições de células t car anti-bcma
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11408005B2
(en)
|
2016-12-12 |
2022-08-09 |
Seattle Children's Hospital |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN106749681A
(zh)
*
|
2017-02-10 |
2017-05-31 |
河南大学淮河医院 |
靶向人FRα的基因工程化NKT细胞及其制备方法和应用
|
|
TWI814525B
(zh)
|
2017-02-14 |
2023-09-01 |
美商凱特製藥公司 |
Ｃｄ７０結合分子及使用彼之方法
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
KR102692556B1
(ko)
|
2017-03-16 |
2024-08-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 변이체 면역조절 단백질 및 그의 용도
|
|
WO2018170023A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
|
CN110662758A
(zh)
|
2017-03-16 |
2020-01-07 |
高山免疫科学股份有限公司 |
Cd80变体免疫调节蛋白及其用途
|
|
CA3054621A1
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
CA3054104A1
(en)
*
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptor formats
|
|
CA3054443A1
(en)
|
2017-04-01 |
2018-10-14 |
Avm Biotechnology, Llc |
Replacement of cytotoxic preconditioning before cellular immunotherapy
|
|
AR111360A1
(es)
|
2017-04-03 |
2019-07-03 |
Kite Pharma Inc |
Tratamiento usando células t de receptor quimérico incorporando células t polifuncionales optimizadas
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
CN110868850B
(zh)
*
|
2017-05-12 |
2023-07-14 |
杰克逊实验室 |
缺乏i类和ii类mhc的nsg小鼠
|
|
CA3061959A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer
|
|
CA3067914A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
WO2019032927A1
(en)
*
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF
|
|
EP3681531A1
(en)
*
|
2017-09-15 |
2020-07-22 |
Kite Pharma, Inc. |
Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
US20190092818A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
Chimeric polypeptides and uses thereof
|
|
JP7749319B2
(ja)
|
2017-10-10 |
2025-10-06 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
PT3697810T
(pt)
|
2017-10-18 |
2026-02-19 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
|
|
WO2019079564A1
(en)
|
2017-10-18 |
2019-04-25 |
Kite Pharma, Inc. |
METHODS OF DELIVERY OF CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
|
|
US11712026B2
(en)
|
2017-10-18 |
2023-08-01 |
The Jackson Laboratory |
Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
|
|
EP3707160A1
(en)
|
2017-11-10 |
2020-09-16 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting tumor antigens
|
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
|
CA3086832A1
(en)
|
2018-01-03 |
2019-07-11 |
Qu Biologics Inc. |
Innate targeting of adoptive cellular therapies
|
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
KR20200110356A
(ko)
|
2018-01-15 |
2020-09-23 |
화이자 인코포레이티드 |
키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법
|
|
AU2019209428B2
(en)
|
2018-01-22 |
2025-06-26 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
|
KR102618231B1
(ko)
|
2018-02-16 |
2023-12-28 |
카이트 파마 인코포레이티드 |
변형된 만능성 줄기 세포, 및 제조 및 사용 방법
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
TW202000229A
(zh)
|
2018-02-23 |
2020-01-01 |
美商安德賽特公司 |
Car t細胞療法之順序方法
|
|
CN112119157B
(zh)
|
2018-03-06 |
2025-01-14 |
宾夕法尼亚大学董事会 |
前列腺特异性膜抗原car及其使用方法
|
|
CN115925952A
(zh)
|
2018-03-13 |
2023-04-07 |
东莞凡恩世生物医药有限公司 |
抗叶酸受体1抗体及其用途
|
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
|
IL310416B1
(en)
|
2018-04-12 |
2025-12-01 |
Kite Pharma Inc |
Chimeric T-cell receptor therapy using tumor microenvironmental characteristics
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
EP4403224A3
(en)
|
2018-06-01 |
2024-07-31 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
|
WO2019236593A1
(en)
*
|
2018-06-05 |
2019-12-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
WO2020005837A1
(en)
*
|
2018-06-25 |
2020-01-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
|
|
JP7623939B2
(ja)
*
|
2018-07-09 |
2025-01-29 |
マルチチュード インコーポレーテッド |
葉酸受容体アルファに特異的な抗体
|
|
IL280329B2
(en)
|
2018-08-02 |
2024-09-01 |
Kite Pharma Inc |
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
|
|
CN110819703A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞安全性的方法
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
|
KR20210089146A
(ko)
|
2018-09-19 |
2021-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
|
|
MX2021003435A
(es)
|
2018-09-28 |
2021-06-15 |
Massachusetts Inst Technology |
Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
|
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
|
CA3113539A1
(en)
*
|
2018-10-10 |
2020-04-16 |
Zymeworks Inc. |
Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof
|
|
CN111197032A
(zh)
*
|
2018-11-16 |
2020-05-26 |
上海斯丹赛生物技术有限公司 |
嵌合抗原受体细胞分泌治疗剂
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
AU2019384145A1
(en)
*
|
2018-11-20 |
2021-06-10 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified cell expressing therapeutic agent and uses thereof
|
|
WO2020113098A1
(en)
|
2018-11-29 |
2020-06-04 |
Vineti Inc. |
Centralized and decentralized individualized medicine platform
|
|
US12227551B2
(en)
|
2018-12-11 |
2025-02-18 |
Obsidian Therapeutics, Inc. |
Membrane bound IL12 compositions and methods for tunable regulation
|
|
CN120005921A
(zh)
|
2018-12-12 |
2025-05-16 |
凯德药业股份有限公司 |
嵌合抗原和t细胞受体及使用的方法
|
|
CN109796535B
(zh)
*
|
2019-01-30 |
2022-11-15 |
重庆福美干细胞生物科技发展有限公司 |
靶向叶酸受体α的嵌合抗原受体及其在制备预防或治疗恶性肿瘤药物中的用途
|
|
US11321652B1
(en)
|
2019-02-20 |
2022-05-03 |
Vineti Inc. |
Smart label devices, systems, and methods
|
|
MX2021010840A
(es)
|
2019-03-08 |
2022-01-19 |
Obsidian Therapeutics Inc |
Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
|
|
CN120944827A
(zh)
*
|
2019-03-27 |
2025-11-14 |
宾夕法尼亚大学董事会 |
Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
|
|
JP2022532865A
(ja)
|
2019-05-03 |
2022-07-20 |
カイト ファーマ インコーポレイテッド |
キメラ抗原受容体免疫療法の投与方法
|
|
MX2021013949A
(es)
*
|
2019-05-13 |
2022-01-04 |
Univ Pennsylvania |
Composiciones y metodos de celulas de receptor de autoanticuerpo quimerico del receptor de acetilcolina.
|
|
WO2020234632A1
(en)
|
2019-05-23 |
2020-11-26 |
Ichorlabs, D.O.O |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
|
US20220267398A1
(en)
|
2019-06-12 |
2022-08-25 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
KR20220044266A
(ko)
|
2019-06-12 |
2022-04-07 |
옵시디안 테라퓨틱스, 인크. |
조정 가능한 조절을 위한 ca2 조성물 및 방법
|
|
US12109235B2
(en)
|
2019-06-21 |
2024-10-08 |
Kite Pharma, Inc. |
TGF-beta receptors and methods of use
|
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
|
AU2020343300B2
(en)
|
2019-09-03 |
2026-01-22 |
Allogene Therapeutics, Inc. |
Methods of preparing T cells for T cell therapy
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
WO2021072312A1
(en)
*
|
2019-10-11 |
2021-04-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting cd13 and tim-3 with car t cells to treat acute myeloid leukemia
|
|
JP2022553200A
(ja)
*
|
2019-10-16 |
2022-12-22 |
ウモジャ バイオファーマ， インコーポレイテッド |
ユニバーサル受容体療法のためのレトロウイルスベクター
|
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
CN115244173A
(zh)
|
2019-12-20 |
2022-10-25 |
英研生物(英国)有限公司 |
用于分离肿瘤浸润淋巴细胞的装置及方法及其用途
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
|
IL296242A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Methods for producing engineered memory-like nk cells and preparations containing them
|
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
IL299886A
(en)
|
2020-07-17 |
2023-03-01 |
Instil Bio Uk Ltd |
Receptors that provide targeted costimulation for host cell therapy
|
|
WO2022036041A1
(en)
|
2020-08-14 |
2022-02-17 |
Kite Pharma, Inc |
Improving immune cell function
|
|
CA3189109A1
(en)
*
|
2020-08-18 |
2022-02-24 |
Jacob CAREY |
Methods and systems for cell-free dna fragment size densities to assess cancer
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
JP2023542539A
(ja)
|
2020-09-24 |
2023-10-10 |
ザ ジャクソン ラボラトリー |
免疫細胞療法を評価するためのヒト化マウスモデル
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
CN116745319A
(zh)
|
2020-12-24 |
2023-09-12 |
凯德药业股份有限公司 |
前列腺癌嵌合抗原受体
|
|
EP4275044A1
(en)
|
2021-01-10 |
2023-11-15 |
Kite Pharma, Inc. |
T cell therapy
|
|
TW202241469A
(zh)
|
2021-02-20 |
2022-11-01 |
美商凱特製藥公司 |
免疫療法
|
|
AU2022234333B2
(en)
|
2021-03-11 |
2025-05-22 |
Kite Pharma, Inc. |
Improving immune cell function
|
|
CN112794911B
(zh)
*
|
2021-04-14 |
2021-08-03 |
上海偌妥生物科技有限公司 |
人源化抗叶酸受体1抗体及其应用
|
|
IL307384A
(en)
|
2021-04-16 |
2023-11-01 |
Kite Pharma Inc |
Molecules with a dual link to TACI and BCMA
|
|
TW202309269A
(zh)
|
2021-04-27 |
2023-03-01 |
日商武田藥品工業股份有限公司 |
重組抗原呈現細胞
|
|
IL308227A
(en)
|
2021-05-14 |
2024-01-01 |
Kite Pharma Inc |
Chimeric antigen receptor t cell therapy
|
|
IL308696A
(en)
|
2021-05-24 |
2024-01-01 |
Kite Pharma Inc |
Nkg2d-based chimeric antgen receptor
|
|
BR112023022097A2
(pt)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
Cxcr5, pd-1 e icos expressando células t cd4 reativas de tumor e seu uso
|
|
AU2022291365B2
(en)
|
2021-06-08 |
2026-03-12 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
|
WO2022266192A1
(en)
|
2021-06-16 |
2022-12-22 |
Instil Bio, Inc. |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
US20230027004A1
(en)
|
2021-07-01 |
2023-01-26 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
|
US20230103457A1
(en)
|
2021-07-02 |
2023-04-06 |
Kite Pharma, Inc. |
Method for identifying variants in gene products from gene constructs used in cell therapy applications
|
|
EP4370213A4
(en)
|
2021-07-16 |
2025-06-04 |
Instil Bio (Uk) Limited |
Chimeric molecules for targeted costimulation for adoptive cell therapy
|
|
US11615874B1
(en)
|
2021-09-30 |
2023-03-28 |
Vineti Inc. |
Personalized medicine and therapies platform
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
IL313935A
(en)
|
2021-12-30 |
2024-08-01 |
Tr1X Inc |
CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof
|
|
CA3247927A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
|
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
WO2023159001A1
(en)
|
2022-02-15 |
2023-08-24 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
|
US20250243260A1
(en)
|
2022-03-07 |
2025-07-31 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
|
|
AU2023282907A1
(en)
|
2022-06-09 |
2024-11-14 |
Kite Pharma, Inc. |
Methods of preparing lymphocytes for cell therapy
|
|
AR130163A1
(es)
|
2022-08-10 |
2024-11-13 |
Takeda Pharmaceuticals Co |
Células modificadas hipoinmunogénicas
|
|
CN120239746A
(zh)
|
2022-09-19 |
2025-07-01 |
图恩疗法股份有限公司 |
用于调节t细胞功能的组合物、系统和方法
|
|
WO2024092152A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Improving efficacy and durable response of immunotherapy
|
|
WO2024092227A1
(en)
|
2022-10-28 |
2024-05-02 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy
|
|
WO2024196689A1
(en)
|
2023-03-17 |
2024-09-26 |
Kite Pharma, Inc. |
Impact of tumor microenvironment on efficacy of immunotherapy
|
|
WO2024206549A2
(en)
*
|
2023-03-29 |
2024-10-03 |
Cellicure, Inc. |
Engineered immune cells and use thereof
|
|
WO2024224359A1
(en)
|
2023-04-27 |
2024-10-31 |
Takeda Pharmaceutical Company Limited |
Method for expanding cd56+/cd3- cells
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025096517A1
(en)
|
2023-11-01 |
2025-05-08 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy efficacy
|
|
WO2025188561A1
(en)
|
2024-03-04 |
2025-09-12 |
Kite Pharma, Inc. |
Predictive markers for immunotherapy
|
|
WO2026015450A1
(en)
|
2024-07-06 |
2026-01-15 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|